The M&A Risk Checklist: 12 Items Strategic Acquirers Miss

← Back to All Insights

Strategic acquirers run rigorous financial and commercial due diligence. They run thorough legal and IP reviews. And yet—roughly 60% of medical device acquisitions fail to deliver the projected synergies, often because the same risks surface across deal after deal. Below is the 12-item checklist Vantage runs on every M&A engagement.

These are not the items your investment bankers will flag. They are the items that show up in the integration phase, when it is far too late to renegotiate price.

1. Predicate Strategy Vulnerability

If the target's lead product was cleared via 510(k), examine the predicate chain back at least two generations. Predicate creep accumulates regulatory fragility that does not appear on the surface. Acquirers who skip this step are surprised when FDA Additional Information requests delay post-close product launches by 12-18 months.

2. CAPA and Recall History Depth

Public recall data only tells you what FDA forced into the public record. Open CAPAs, customer complaints under investigation, and field corrections that have not yet been classified as recalls all live in the quality system. Get full access to the Quality Management System data—not summaries—or assume undisclosed exposure.

3. Reimbursement Coverage Stability

Coverage today is not coverage tomorrow. Examine the LCDs (Local Coverage Determinations) underlying the target's revenue, the NCDs (National Coverage Determinations) being reconsidered, and any pending CMS Hospital Outpatient Prospective Payment System rule changes. A 2% APC adjustment can move a profitable product into negative gross margin overnight.

4. Real-World Evidence Obligations

Many recent FDA clearances come with post-approval study (PAS) commitments. These obligations transfer with the product and can cost $2-15M to complete. Acquirers regularly discover these obligations after close. Pull the FDA correspondence file before signing.

5. Quality System Scalability

A QMS that worked at 2,000 units per month may not pass FDA inspection at 20,000 units per month. Examine the QMS sophistication relative to the target's growth plan. Hidden gap: most early-stage device companies have QMS infrastructure designed for clearance, not for the scale the deal model assumes.

6. Manufacturing Single Points of Failure

Sole-source components, single-site sterilization, or one-supplier raw materials are common in medical devices and rarely surface in CIM materials. Audit the bill of materials for parts with only one validated supplier. Each one is an integration risk and often a 6-12 month qualification gap for a backup.

7. Clinical Trial Sites and Investigator Stability

If the target has active clinical trials, examine the investigator agreements, the site contracts, and the data ownership clauses. Investigator turnover post-close can stall enrollment for 6+ months. Site closures during integration are common and rarely disclosed.

8. Cybersecurity Posture

Connected devices face mandatory FDA cybersecurity requirements under the 2023 omnibus. Examine the target's Software Bill of Materials (SBOM), penetration test history, and vulnerability disclosure response time. The FDA can demand updates post-close at acquirer's cost.

9. Intellectual Property Freedom-to-Operate

Standard IP diligence covers what the target owns. Freedom-to-operate analyzes what they could be sued over. A surprising number of growth-stage medical device companies have FTO gaps their counsel discounted as low-probability. After close, the acquirer owns the litigation risk.

10. Key Personnel Retention Obligations

Identify the 3-5 people whose departure would materially impair the business. Examine their existing comp, equity vesting, and any non-compete enforceability under the relevant state law (California enforceability is essentially zero). Build retention into the deal, not after.

11. Customer Concentration and Switching Cost

What looks like a strong customer base may be 3 hospital systems that account for 60% of revenue, each with annual contracts. Examine churn cohorts, win/loss data, and customer satisfaction scores by segment. Concentrated revenue is concentrated execution risk.

12. Regulatory Submission Pipeline Status

Pre-submission packages, in-progress 510(k) filings, and pending De Novo requests carry their own clearance probabilities. Map every active submission against historical FDA clearance rates for similar device classes. This is where the deal model's pipeline assumptions get tested.

Most failed medical device acquisitions trace to one or more of these twelve items. The pattern is not new; the discipline of running all twelve—every time—is what separates acquirers who consistently deliver synergies from those who consistently disappoint their boards.